Clinical Trials Finder
Independent ClinicalTrials.gov directory
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced May 22, 2026, 12:00 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 25–46 of 22 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Condition: Homologous Recombination Deficiency Clear all
Completed Phase 1 Interventional
View directory record Official record
Conditions
Pancreatic Cancer
Interventions
Whole liver irradiation (WLI), Gemcitabine and Cisplatin
Radiation · Drug
Lead sponsor
Memorial Sloan Kettering Cancer Center
Other
Eligibility
18 Years and older
Enrollment
1 participant
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2024
U.S. locations
7
States / cities
Basking Ridge, New Jersey • Middletown, New Jersey • Montvale, New Jersey + 4 more
Source: ClinicalTrials.gov public record
Updated Nov 11, 2024 · Synced May 22, 2026, 12:00 AM EDT
Recruiting Phase 1Phase 2 Interventional
View directory record Official record
Conditions
Solid Tumours
Interventions
AZD4956, Saruparib
Drug
Lead sponsor
AstraZeneca
Industry
Eligibility
18 Years to 130 Years
Enrollment
180 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2030
U.S. locations
4
States / cities
New York, New York • Providence, Rhode Island • Houston, Texas + 1 more
Source: ClinicalTrials.gov public record
Updated Apr 19, 2026 · Synced May 22, 2026, 12:00 AM EDT
Completed Phase 1 Interventional
View directory record Official record
Conditions
Advanced Malignant Solid Neoplasm, Refractory Malignant Solid Neoplasm
Interventions
Cabozantinib, Pamiparib
Drug
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
18 Years and older
Enrollment
44 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2026
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated May 11, 2026 · Synced May 22, 2026, 12:00 AM EDT
Active, not recruiting Phase 2 Interventional
View directory record Official record
Conditions
Advanced Solid Neoplasms
Interventions
Olaparib
Drug
Lead sponsor
Merck Sharp & Dohme LLC
Industry
Eligibility
18 Years and older
Enrollment
329 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2026
U.S. locations
24
States / cities
Tucson, Arizona • Fullerton, California • Los Angeles, California + 17 more
Source: ClinicalTrials.gov public record
Updated May 14, 2026 · Synced May 22, 2026, 12:00 AM EDT
Completed Phase 3 Interventional Results available
View directory record Official record
Conditions
Ovarian Cancer, Epithelial Ovarian Cancer, Fallopian Tube Cancer, Peritoneal Cancer
Interventions
Chemotherapy, Rucaparib
Drug
Lead sponsor
pharmaand GmbH
Industry
Eligibility
18 Years and older · Female only
Enrollment
349 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2022
U.S. locations
2
States / cities
Denver, Colorado • Augusta, Georgia
Source: ClinicalTrials.gov public record
Updated Jun 8, 2023 · Synced May 22, 2026, 12:00 AM EDT
Active, not recruiting Phase 2 Interventional
View directory record Official record
Conditions
Solid Tumors
Interventions
Olaparib, Pembrolizumab
Drug · Biological
Lead sponsor
Merck Sharp & Dohme LLC
Industry
Eligibility
18 Years and older
Enrollment
300 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2026
U.S. locations
21
States / cities
Birmingham, Alabama • Gilbert, Arizona • Sacramento, California + 16 more
Source: ClinicalTrials.gov public record
Updated Apr 21, 2026 · Synced May 22, 2026, 12:00 AM EDT
Terminated Phase 2 Interventional Results available
View directory record Official record
Conditions
Castration-Resistant Prostate Carcinoma, Prostate Adenocarcinoma
Interventions
Olaparib
Drug
Lead sponsor
University of Washington
Other
Eligibility
18 Years and older · Male only
Enrollment
2 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2023
U.S. locations
1
States / cities
Seattle, Washington
Source: ClinicalTrials.gov public record
Updated Dec 31, 2024 · Synced May 22, 2026, 12:00 AM EDT
Recruiting Phase 2 Interventional
View directory record Official record
Conditions
Metastatic Castrate Resistant Prostate Cancer, BARD1, BRCA1, BRCA2, BRIP1, CHEK1, FANCL, PALB2, RAD51B, RAD51C, RAD51D, or RAD54L Mutations
Interventions
Carboplatin, Olaparib
Drug
Lead sponsor
VA Office of Research and Development
Federal
Eligibility
18 Years and older · Male only
Enrollment
100 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2027
U.S. locations
18
States / cities
West Los Angeles, California • Aurora, Colorado • Washington D.C., District of Columbia + 15 more
Source: ClinicalTrials.gov public record
Updated Aug 19, 2025 · Synced May 22, 2026, 12:00 AM EDT
Recruiting Phase 2 Interventional
View directory record Official record
Conditions
Mesothelioma, Homologous Recombination Deficiency
Interventions
Olaparib
Drug
Lead sponsor
University of Chicago
Other
Eligibility
18 Years and older
Enrollment
56 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2028
U.S. locations
1
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated May 5, 2025 · Synced May 22, 2026, 12:00 AM EDT
Recruiting Phase 1Phase 2 Interventional
View directory record Official record
Conditions
Advanced Solid Tumor, Homologous Recombination Deficiency, HRR Deficiency
Interventions
EIS-12656, Olaparib, Trastuzumab deruxtecan
Drug
Lead sponsor
Eisbach Bio GmbH
Industry
Eligibility
18 Years and older
Enrollment
144 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2027
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Sep 18, 2024 · Synced May 22, 2026, 12:00 AM EDT
Active, not recruiting Phase 1Phase 2 Interventional
View directory record Official record
Conditions
HRD Cancer, SCLC, Advanced Solid Tumors
Interventions
Berzosertib, Sacituzumab Govitecan
Drug
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years to 120 Years
Enrollment
35 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2029
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated May 17, 2026 · Synced May 22, 2026, 12:00 AM EDT
Completed Phase 2 Interventional Results available
View directory record Official record
Conditions
Solid Tumor, Adult
Interventions
Pembrolizumab 200 mg Q3W
Drug
Lead sponsor
Baptist Health South Florida
Other
Eligibility
18 Years to 99 Years
Enrollment
52 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2022
U.S. locations
1
States / cities
Miami, Florida
Source: ClinicalTrials.gov public record
Updated Oct 18, 2023 · Synced May 22, 2026, 12:00 AM EDT
Completed Phase 2 Interventional Results available
View directory record Official record
Conditions
Ovarian Cancer, Epithelial Ovarian Cancer, Fallopian Tube Cancer, Peritoneal Cancer
Interventions
Oral rucaparib
Drug
Lead sponsor
pharmaand GmbH
Industry
Eligibility
18 Years and older · Female only
Enrollment
491 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2021
U.S. locations
36
States / cities
Anchorage, Alaska • Tucson, Arizona • Fullerton, California + 28 more
Source: ClinicalTrials.gov public record
Updated Jun 11, 2023 · Synced May 22, 2026, 12:00 AM EDT
Recruiting Phase 1 Interventional
View directory record Official record
Conditions
Advanced Solid Tumor
Interventions
CX-5461
Drug
Lead sponsor
Senhwa Biosciences, Inc.
Industry
Eligibility
18 Years and older
Enrollment
52 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2027
U.S. locations
6
States / cities
Santa Monica, California • Tampa, Florida • Boston, Massachusetts + 3 more
Source: ClinicalTrials.gov public record
Updated Apr 27, 2026 · Synced May 22, 2026, 12:00 AM EDT
Completed No phase listed Observational
View directory record Official record
Conditions
Advanced Ovarian Cancer
Interventions
None (Observational Study)
Other
Lead sponsor
AstraZeneca
Industry
Eligibility
18 Years to 130 Years · Female only
Enrollment
24 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023
U.S. locations
7
States / cities
Tampa, Florida • Shreveport, Louisiana • Annapolis, Maryland + 4 more
Source: ClinicalTrials.gov public record
Updated Sep 19, 2024 · Synced May 22, 2026, 12:00 AM EDT
Active, not recruiting Phase 2 Interventional
View directory record Official record
Conditions
Metastatic Pancreatic Ductal Adenocarcinoma, Homologous Recombination Deficiency (HRD)
Interventions
Pembrolizumab, Olaparib
Drug
Lead sponsor
Memorial Sloan Kettering Cancer Center
Other
Eligibility
18 Years and older
Enrollment
63 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2027
U.S. locations
7
States / cities
Middletown, New Jersey • Montvale, New Jersey • Commack, New York + 3 more
Source: ClinicalTrials.gov public record
Updated Feb 17, 2026 · Synced May 22, 2026, 12:00 AM EDT
Completed Phase 2 Interventional
View directory record Official record
Conditions
Metastatic Castration-Resistant Prostate Cancer
Interventions
vudalimab + carboplatin + cabazitaxel, vudalimab + olaparib, vudalimab monotherapy, vudalimab + docetaxel, vudalimab + cabazitaxel or docetaxel
Combination Product · Biological
Lead sponsor
Xencor, Inc.
Industry
Eligibility
18 Years and older · Male only
Enrollment
72 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2025
U.S. locations
26
States / cities
Anchorage, Alaska • Glendale, Arizona • Phoenix, Arizona + 23 more
Source: ClinicalTrials.gov public record
Updated May 4, 2026 · Synced May 22, 2026, 12:00 AM EDT
Completed Phase 2 Interventional Results available
View directory record Official record
Conditions
Advanced Cancers
Interventions
LY2606368
Drug
Lead sponsor
Dana-Farber Cancer Institute
Other
Eligibility
18 Years and older
Enrollment
27 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2021
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Oct 20, 2022 · Synced May 22, 2026, 12:00 AM EDT
Not listed Phase 2 Interventional
View directory record Official record
Conditions
Homologous Recombination Deficient Solid Tumors
Interventions
Combination drug
Drug
Lead sponsor
West Cancer Center
Other
Eligibility
Up to 100 Years
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2025
U.S. locations
1
States / cities
Germantown, Tennessee
Source: ClinicalTrials.gov public record
Updated Dec 20, 2023 · Synced May 22, 2026, 12:00 AM EDT
Active, not recruiting Phase 2 Interventional
View directory record Official record
Conditions
Ovarian Cancer
Interventions
Tuvusertib (M1774), Niraparib, Lartesertib (M4076)
Drug
Lead sponsor
EMD Serono Research & Development Institute, Inc.
Industry
Eligibility
18 Years and older · Female only
Enrollment
63 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2026
U.S. locations
9
States / cities
Little Rock, Arkansas • San Francisco, California • Columbus, Georgia + 4 more
Source: ClinicalTrials.gov public record
Updated Feb 17, 2026 · Synced May 22, 2026, 12:00 AM EDT
Recruiting Phase 3 Interventional
View directory record Official record
Conditions
Fallopian Tube Endometrioid Adenocarcinoma, Fallopian Tube High Grade Serous Adenocarcinoma, FIGO Stage III Ovarian Cancer 2014, FIGO Stage IV Ovarian Cancer 2014, Ovarian Carcinoma, Ovarian High Grade Endometrioid Adenocarcinoma, Ovarian High Grade Serous Adenocarcinoma, Primary Peritoneal Endometrioid Adenocarcinoma, Primary Peritoneal High Grade Serous Adenocarcinoma
Interventions
Bevacizumab, Biospecimen Collection, Computed Tomography, Magnetic Resonance Imaging, Olaparib
Biological · Procedure · Drug
Lead sponsor
NRG Oncology
Other
Eligibility
18 Years and older
Enrollment
880 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2034
U.S. locations
658
States / cities
Birmingham, Alabama • Anchorage, Alaska • Phoenix, Arizona + 447 more
Source: ClinicalTrials.gov public record
Updated Mar 23, 2026 · Synced May 22, 2026, 12:00 AM EDT
Terminated Phase 2 Interventional Results available
View directory record Official record
Conditions
Ovarian Neoplasms
Interventions
Niraparib, Carboplatin, Paclitaxel
Drug
Lead sponsor
Tesaro, Inc.
Industry
Eligibility
18 Years and older · Female only
Enrollment
36 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2025
U.S. locations
11
States / cities
San Francisco, California • Miami, Florida • Tampa, Florida + 7 more
Source: ClinicalTrials.gov public record
Updated Nov 25, 2025 · Synced May 22, 2026, 12:00 AM EDT